Coronaviruses and their therapy
Identifieur interne : 000495 ( PascalFrancis/Checkpoint ); précédent : 000494; suivant : 000496Coronaviruses and their therapy
Auteurs : Bart L. Haagmans [Pays-Bas] ; Albert D. M. E. Osterhaus [Pays-Bas]Source :
- Antiviral research [ 0166-3542 ] ; 2006.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Coronaviruses may cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses hampered development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has prompted the discovery of such drugs. Subsequent studies in animal models demonstrated the efficacy of SARS-CoV specific monoclonal antibodies, pegylated-interferon-a and siRNAs against SARS-CoV. Furthermore, several antivirals shown to be effective against other viruses were tested in vitro. Because of availability and shown efficacy, the use of interferons may be considered should SARS-CoV or a related coronavirus (re)-emerge. The more recent design of wide-spectrum inhibitors targeting the coronavirus main proteases may lead to the discovery of new antivirals against multiple coronavirus induced diseases.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:06-0491674Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Coronaviruses and their therapy</title><author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0491674</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0491674 INIST</idno><idno type="RBID">Pascal:06-0491674</idno><idno type="wicri:Area/PascalFrancis/Corpus">000451</idno><idno type="wicri:Area/PascalFrancis/Curation">000539</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000495</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000495</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Coronaviruses and their therapy</title><author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antiviral research</title><title level="j" type="abbreviated">Antivir. res.</title><idno type="ISSN">0166-3542</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term><term>Coronavirus</term><term>Fusion inhibitor</term><term>Review</term><term>Severe acute respiratory syndrome</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Traitement</term><term>Article synthèse</term><term>Syndrome respiratoire aigu sévère</term><term>Antiviral</term><term>Coronavirus</term><term>Inhibiteur d'entrée</term><term>inhibiteur de réplication</term><term>Inhibiteur de fusion</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronaviruses may cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses hampered development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has prompted the discovery of such drugs. Subsequent studies in animal models demonstrated the efficacy of SARS-CoV specific monoclonal antibodies, pegylated-interferon-a and siRNAs against SARS-CoV. Furthermore, several antivirals shown to be effective against other viruses were tested in vitro. Because of availability and shown efficacy, the use of interferons may be considered should SARS-CoV or a related coronavirus (re)-emerge. The more recent design of wide-spectrum inhibitors targeting the coronavirus main proteases may lead to the discovery of new antivirals against multiple coronavirus induced diseases.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-3542</s0></fA01><fA02 i1="01"><s0>ARSRDR</s0></fA02><fA03 i2="1"><s0>Antivir. res.</s0></fA03><fA05><s2>71</s2></fA05><fA06><s2>2-3</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Coronaviruses and their therapy</s1></fA08><fA11 i1="01" i2="1"><s1>HAAGMANS (Bart L.)</s1></fA11><fA11 i1="02" i2="1"><s1>OSTERHAUS (Albert D. M. E.)</s1></fA11><fA14 i1="01"><s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1><s2>3015 GE Rotterdam</s2><s3>NLD</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></fA14><fA20><s1>397-403</s1></fA20><fA21><s1>2006</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>18839</s2><s5>354000142317820390</s5></fA43><fA44><s0>0000</s0><s1>© 2006 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>2 p.</s0></fA45><fA47 i1="01" i2="1"><s0>06-0491674</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Antiviral research</s0></fA64><fA66 i1="01"><s0>NLD</s0></fA66><fC01 i1="01" l="ENG"><s0>Coronaviruses may cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses hampered development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has prompted the discovery of such drugs. Subsequent studies in animal models demonstrated the efficacy of SARS-CoV specific monoclonal antibodies, pegylated-interferon-a and siRNAs against SARS-CoV. Furthermore, several antivirals shown to be effective against other viruses were tested in vitro. Because of availability and shown efficacy, the use of interferons may be considered should SARS-CoV or a related coronavirus (re)-emerge. The more recent design of wide-spectrum inhibitors targeting the coronavirus main proteases may lead to the discovery of new antivirals against multiple coronavirus induced diseases.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02S05</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Traitement</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Treatment</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Tratamiento</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Article synthèse</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Review</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Artículo síntesis</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0><s2>NM</s2><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0><s2>NM</s2><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0><s2>NM</s2><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Antiviral</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Antiviral</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Antiviral</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Coronavirus</s0><s2>NW</s2><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Coronavirus</s0><s2>NW</s2><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Coronavirus</s0><s2>NW</s2><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Inhibiteur d'entrée</s0><s4>INC</s4><s5>86</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>inhibiteur de réplication</s0><s4>INC</s4><s5>87</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Inhibiteur de fusion</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Fusion inhibitor</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Inhibidor fusión</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Respiratory disease</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0><s5>37</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Poumon pathologie</s0><s5>38</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0><s5>38</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0><s5>38</s5></fC07><fN21><s1>317</s1></fN21></pA></standard></inist><affiliations><list><country><li>Pays-Bas</li></country></list><tree><country name="Pays-Bas"><noRegion><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name></noRegion><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000495 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000495 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:06-0491674
|texte= Coronaviruses and their therapy
}}
| This area was generated with Dilib version V0.6.33. |  |